5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 30.71▲ | 30.63▲ | 30.63▲ | 30.95▲ | 30.93▲ |
MA10 | 30.38▲ | 30.30▲ | 30.30▲ | 30.96▲ | 30.69▲ |
MA20 | 29.45▲ | 29.32▲ | 29.32▲ | 30.89▲ | 30.24▲ |
MA50 | 27.97▲ | 27.89▲ | 27.88▲ | 30.58▲ | 28.60▲ |
MA100 | 27.42▲ | 27.42▲ | 27.42▲ | 30.09▲ | N/A |
MA200 | 26.90▲ | N/A | N/A | 28.82▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.063▲ | 0.091▲ | 0.091▲ | -0.012▼ | 0.007▲ |
RSI | 72.046▲ | 71.990▲ | 71.956▲ | 63.563▲ | 68.595▲ |
STOCH | 93.176▲ | 94.859▲ | 94.859▲ | 65.681 | 92.887▲ |
WILL %R | -16.466▲ | -7.143▲ | -7.143▲ | -6.933▲ | -1.704▲ |
CCI | 91.272 | 104.411▲ | 104.411▲ | 179.578▲ | 105.687▲ |
Monday, September 29, 2025 03:42 AM
Japanese drugmaker Eisai and US biotech major Biogen’s humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been approved for once every four weeks ...
|
Sunday, September 28, 2025 04:40 PM
In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/09/25 | 31.10 | 31.10 | 31.074 | 31.074 | 300 |
29/09/25 | 31.023 | 31.023 | 31.023 | 31.023 | 100 |
26/09/25 | 30.9591 | 30.9591 | 30.9591 | 30.9591 | 40 |
25/09/25 | 30.75 | 30.8085 | 30.725 | 30.8085 | 736 |
24/09/25 | 30.9038 | 30.9038 | 30.9038 | 30.9038 | 24 |
23/09/25 | 30.9747 | 30.9747 | 30.9747 | 30.9747 | 8 |
22/09/25 | 30.93 | 31.0036 | 30.93 | 31.0036 | 3,004 |
19/09/25 | 30.9665 | 30.9665 | 30.9665 | 30.9665 | 0 |
18/09/25 | 30.993 | 30.993 | 30.993 | 30.993 | 200 |
17/09/25 | 30.901 | 30.95 | 30.90 | 30.9382 | 1,010 |
|
|
||||
|
|
||||
|
|